WGU D116 Advanced Pharmacology OA & Pre-Assessment
Exam Bank Actual Exam 2026/2027 | Questions with Verified
Answers | 100% Correct | Pass Guaranteed|100+ Questions.
Section 1: Foundational Principles & Pharmacokinetics
Q1. A patient with hepatic impairment is prescribed a prodrug that requires conversion in
the liver to become active. The nurse anticipates which alteration in therapeutic effect?
A. Increased therapeutic effect due to altered absorption
B. Decreased therapeutic effect due to reduced metabolism
C. No change in therapeutic effect due to passive diffusion
D. Increased risk for toxicity due to protein binding changes
Answer: B. Decreased therapeutic effect due to reduced metabolism
Rationale: A prodrug is inactive until metabolized by the liver. In hepatic impairment, this
conversion is slowed or reduced, leading to lower levels of the active drug and diminished
therapeutic effects .
Q2. A patient with chronic kidney disease (CKD) is receiving a medication primarily
excreted unchanged by the kidneys. The prescribers decision to reduce the dose is based
on changes in which pharmacokinetic process?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Answer: D. Excretion
Rationale: The kidneys are the primary site of drug excretion. In CKD, glomerular filtration
rate (GFR) declines, reducing drug clearance and prolonging half-life. Dose reduction
prevents drug accumulation and toxicity .
Q3. Which factor most significantly increases the volume of distribution (Vd) for a
lipophilic drug like diazepam in an elderly patient?
A. Decreased cardiac output
B. Increased body fat percentage
C. Reduced serum albumin levels
D. Decreased hepatic blood flow
Answer: B. Increased body fat percentage
Rationale: Lipophilic drugs distribute into adipose tissue. Age-related increase in body fat
, provides a larger reservoir for these drugs, increasing Vd and prolonging their half-life as
they are slowly released .
Q4. A drug is known to be a strong CYP3A4 inhibitor. When this drug is added to a patients
regimen that includes a CYP3A4 substrate, the nurse expects:
A. Decreased levels of the substrate drug
B. Increased levels of the substrate drug
C. No change in substrate drug levels
D. Increased excretion of the substrate drug
Answer: B. Increased levels of the substrate drug
Rationale: CYP450 enzymes metabolize drugs. An inhibitor slows this metabolism. If
metabolism slows, the drug accumulates, leading to higher serum concentrations and
increased risk of toxicity or therapeutic effect .
Q5. A patient receiving a drug with a half-life of 24 hours asks when steady state will be
achieved. The nurse correctly states steady state is typically reached in:
A. 24-48 hours
B. 3-4 days
C. 4-6 days
D. 7-10 days
Answer: C. 4-6 days
Rationale: Steady state is achieved after approximately 4-5 half-lives. With a 24-hour half-
life, this equates to 4-5 days (96-120 hours), where drug accumulation and elimination reach
equilibrium .
Section 2: Cardiovascular & Hematologic Pharmacology
Q6. A nurse is administering digoxin to a patient with heart failure. Which assessment
finding requires withholding the dose and notifying the provider?
A. Apical pulse of 78 bpm
B. Serum potassium of 4.0 mEq/L
C. Apical pulse of 52 bpm
D. Blood pressure of 120/80 mmHg
Answer: C. Apical pulse of 52 bpm
Rationale: Digoxin slows the heart rate by inhibiting the Na+/K+ ATPase pump. Standard
safety parameters require holding the dose for an apical pulse below 60 bpm in an adult to
avoid worsening bradycardia or heart block .
Q7. A patient receiving IV furosemide (Lasix) reports sudden onset tinnitus. What is the
nurse's priority action?
A. Reassure the patient this is a normal side effect
Exam Bank Actual Exam 2026/2027 | Questions with Verified
Answers | 100% Correct | Pass Guaranteed|100+ Questions.
Section 1: Foundational Principles & Pharmacokinetics
Q1. A patient with hepatic impairment is prescribed a prodrug that requires conversion in
the liver to become active. The nurse anticipates which alteration in therapeutic effect?
A. Increased therapeutic effect due to altered absorption
B. Decreased therapeutic effect due to reduced metabolism
C. No change in therapeutic effect due to passive diffusion
D. Increased risk for toxicity due to protein binding changes
Answer: B. Decreased therapeutic effect due to reduced metabolism
Rationale: A prodrug is inactive until metabolized by the liver. In hepatic impairment, this
conversion is slowed or reduced, leading to lower levels of the active drug and diminished
therapeutic effects .
Q2. A patient with chronic kidney disease (CKD) is receiving a medication primarily
excreted unchanged by the kidneys. The prescribers decision to reduce the dose is based
on changes in which pharmacokinetic process?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Answer: D. Excretion
Rationale: The kidneys are the primary site of drug excretion. In CKD, glomerular filtration
rate (GFR) declines, reducing drug clearance and prolonging half-life. Dose reduction
prevents drug accumulation and toxicity .
Q3. Which factor most significantly increases the volume of distribution (Vd) for a
lipophilic drug like diazepam in an elderly patient?
A. Decreased cardiac output
B. Increased body fat percentage
C. Reduced serum albumin levels
D. Decreased hepatic blood flow
Answer: B. Increased body fat percentage
Rationale: Lipophilic drugs distribute into adipose tissue. Age-related increase in body fat
, provides a larger reservoir for these drugs, increasing Vd and prolonging their half-life as
they are slowly released .
Q4. A drug is known to be a strong CYP3A4 inhibitor. When this drug is added to a patients
regimen that includes a CYP3A4 substrate, the nurse expects:
A. Decreased levels of the substrate drug
B. Increased levels of the substrate drug
C. No change in substrate drug levels
D. Increased excretion of the substrate drug
Answer: B. Increased levels of the substrate drug
Rationale: CYP450 enzymes metabolize drugs. An inhibitor slows this metabolism. If
metabolism slows, the drug accumulates, leading to higher serum concentrations and
increased risk of toxicity or therapeutic effect .
Q5. A patient receiving a drug with a half-life of 24 hours asks when steady state will be
achieved. The nurse correctly states steady state is typically reached in:
A. 24-48 hours
B. 3-4 days
C. 4-6 days
D. 7-10 days
Answer: C. 4-6 days
Rationale: Steady state is achieved after approximately 4-5 half-lives. With a 24-hour half-
life, this equates to 4-5 days (96-120 hours), where drug accumulation and elimination reach
equilibrium .
Section 2: Cardiovascular & Hematologic Pharmacology
Q6. A nurse is administering digoxin to a patient with heart failure. Which assessment
finding requires withholding the dose and notifying the provider?
A. Apical pulse of 78 bpm
B. Serum potassium of 4.0 mEq/L
C. Apical pulse of 52 bpm
D. Blood pressure of 120/80 mmHg
Answer: C. Apical pulse of 52 bpm
Rationale: Digoxin slows the heart rate by inhibiting the Na+/K+ ATPase pump. Standard
safety parameters require holding the dose for an apical pulse below 60 bpm in an adult to
avoid worsening bradycardia or heart block .
Q7. A patient receiving IV furosemide (Lasix) reports sudden onset tinnitus. What is the
nurse's priority action?
A. Reassure the patient this is a normal side effect
